Details for New Drug Application (NDA): 022116
✉ Email this page to a colleague
The generic ingredient in LEXIVA is fosamprenavir calcium. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fosamprenavir calcium profile page.
Summary for 022116
Tradename: | LEXIVA |
Applicant: | Viiv Hlthcare |
Ingredient: | fosamprenavir calcium |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 022116
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LEXIVA | fosamprenavir calcium | SUSPENSION;ORAL | 022116 | NDA | ViiV Healthcare Company | 49702-208 | 49702-208-53 | 225 mL in 1 BOTTLE (49702-208-53) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | EQ 50MG BASE/ML | ||||
Approval Date: | Jun 14, 2007 | TE: | RLD: | Yes |
Expired US Patents for NDA 022116
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | LEXIVA | fosamprenavir calcium | SUSPENSION;ORAL | 022116-001 | Jun 14, 2007 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription